FIELD: medicine.
SUBSTANCE: invention relates to the use of 4-((5,10-dimethyl-6-oxo-6,10-dihydro-5H-pyrimido[5,4-b]thieno[3,2-e][1,4]diazepin-2-yl)amino)benzenesulfonamide (XMU-MP-1) to inhibit the growth of Burkitt's lymphoma cells.
EFFECT: above invention makes it possible to create highly effective selective and low-toxic combinations of antitumor drugs for the treatment of Burkitt's lymphoma.
1 cl, 2 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS OF TREATING CANCER USING APILIMOD | 2016 |
|
RU2738934C2 |
ANTIPROLIFERATIVE AGENT | 2016 |
|
RU2629824C1 |
THIENO[3,2-c]PYRIDINE DERIVATIVES AS KINASE INHIBITORS FOR USE IN CANCER TREATMENT | 2009 |
|
RU2480472C2 |
COMBINATIONS AND USE THEREOF | 2016 |
|
RU2767063C2 |
METHOD FOR PREDICTION OF RECURRENCE IN PATIENTS WITH BASAL CELL CARCINOMA OF SKIN AFTER SURGICAL REMOVAL OF TUMOUR | 2024 |
|
RU2823211C1 |
PIM1-KINASE INHIBITOR 6-[(4-METHYL-I-1-PIPERAZINYL)METHYL]-INDOLO[1',7':1,2,3]PYRROLO[3',4':6,7]AZEPINO[4,5-b]INDOLE-1,3(2H, 10H)-DIONE, METHOD FOR PREPARING AND USING IT | 2011 |
|
RU2466132C1 |
POLYPEPTIDES FOR TREATING ONCOLOGICAL DISEASES | 2017 |
|
RU2728870C2 |
APPLICATION OF PROTEIN EXTRACT AS ANTIPROLIFERATIVE AND CYTOTOXIC AGENT | 2017 |
|
RU2671632C1 |
THERAPEUTIC AGENT FOR BLOOD CANCER TREATMENT | 2018 |
|
RU2751233C2 |
N-(2-(2-(2-AZIDOETHOXY)ETHOXY)ETHYL)-4,6-DI(AZIRIDIN-1-YL)-1,3,5-TRIAZIN-2-AMINE, HAVING CYTOTOXIC ACTION | 2023 |
|
RU2825828C1 |
Authors
Dates
2024-02-21—Published
2023-11-17—Filed